We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
However, investor focus quickly shifted when the company announced a longer-term financial outlook at its Analyst Day event last week. While management provided greater visibility into future spending requirements, it offered limited clarity on the revenue growth needed to support these commitments. This led investors to question the sustainability of its financial recovery.
Rising Spending Commitments Test Fiscal Sustainability for MRNA
At Analyst Day, Moderna outlined cash costs of approximately $4 billion in 2027, rising to $4.0-$4.5 billion annually through 2030, primarily driven by planned investments in oncology. However, the absence of a corresponding multi-year revenue guidance leaves investors with limited visibility into how quickly the company's commercial business can scale to support these spending commitments.
Moderna expects to end 2026 with approximately $9 billion in total liquidity, including cash, investments and undrawn borrowing capacity. While this provides a substantial financial cushion, it does not necessarily indicate that the business is generating sufficient cash internally to sustain its operations and investments. The key question is whether its expanding commercial portfolio can generate enough recurring cash flow to fund its pipeline ambitions without continued reliance on external financing.
An Expanding Portfolio Could Support Revenue Growth for Moderna
Moderna is seeking to reduce its dependence on COVID-19 vaccines by expanding its respiratory portfolio across influenza, RSV and combination vaccines. The company recently launched its influenza vaccine, mFlusiva, in the United States. During the event, management noted that the product recorded more than 110,000 vaccinations during its limited U.S. launch, despite approval coming after the contracting cycle. A broader commercial rollout during the 2027-28 respiratory season could therefore provide a more meaningful contribution to revenues. The company is also looking to expand sales of its next-generation COVID vaccine, mNexspike, and RSV vaccine, mResvia.
International expansion could provide another source of growth. Moderna is looking to strengthen its presence in Europe as a major competitor's vaccine-supply contract expires in 2027, potentially creating an opportunity to capture additional market share. The company estimates the European respiratory vaccine-supply market at approximately 90 million doses across influenza, COVID-19 and RSV. Meanwhile, government partnerships in international markets such as the United Kingdom, Canada, Australia, Mexico and Taiwan are supporting international sales and providing greater revenue visibility.
Despite these diversification efforts, COVID-19 vaccines remain an important contributor to Moderna's commercial business. The company continues to maintain a strong competitive position, supported by its updated vaccines and established distribution network. However, demand has normalized from pandemic-era levels, making sustained growth increasingly challenging. The recent increase in international COVID-19 sales highlights the continued importance of this franchise, but the successful commercialization of newer products will be essential to reducing revenues concentration over time.
Beyond infectious diseases, Moderna's oncology pipeline offers another potential source of future growth. The company’s individualized cancer therapy, intismeran autogene, developed in partnership with Merck (MRK - Free Report) , reported positive phase III results in high-risk melanoma, reducing the risk of recurrence or death by 42%. Both companies are targeting an FDA regulatory submission before the end of 2026, potentially paving the way for approval in 2027. While this could eventually provide a meaningful additional revenue stream, regulatory approval, manufacturing scale-up and commercial adoption remain important uncertainties.
Moderna Faces Stiff Competition in Targeted Markets
Moderna continues to face stiff competition in the COVID-19 vaccine market, where it competes with Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Sanofi/Novavax. As demand for COVID-19 vaccines has normalized, maintaining market share remains important to the company’s respiratory business. Competition could intensify further in the combination vaccines market as manufacturers develop products targeting both influenza and COVID-19, potentially increasing pressure on pricing and market share.
In RSV, Moderna’s mResvia competes with Pfizer’s Abrysvo and GSK’s Arexvy. The seasonal influenza market presents another challenge, with mFlusiva entering a market dominated by established players such as Sanofi, CSL Seqirus and GSK. Competition could become more intense as GSK advances its own mRNA-based flu vaccine following positive phase II results.
MRNA’s Price Performance, Valuation & Estimates
Shares of Moderna have skyrocketed 567% year-to-date, significantly outperforming the industry’s nearly 6% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 29.73 times forward 12-month sales, higher than the industry average of 2.01 times.
Image Source: Zacks Investment Research
Estimates for Moderna’s 2026 loss per share have improved from $8.31 to $7.19 in the past 30 days. During the same time frame, those for 2027 have improved from $4.46 to $3.69.
Image: Shutterstock
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
Key Takeaways
Moderna (MRNA - Free Report) reported better-than-expected third-quarter 2026 results at the start of this month, with both earnings and sales beating expectations. The company also raised its full-year 2026 revenue growth guidance to 15-25% year over year, up from its previous expectation of up to 10%.
However, investor focus quickly shifted when the company announced a longer-term financial outlook at its Analyst Day event last week. While management provided greater visibility into future spending requirements, it offered limited clarity on the revenue growth needed to support these commitments. This led investors to question the sustainability of its financial recovery.
Rising Spending Commitments Test Fiscal Sustainability for MRNA
At Analyst Day, Moderna outlined cash costs of approximately $4 billion in 2027, rising to $4.0-$4.5 billion annually through 2030, primarily driven by planned investments in oncology. However, the absence of a corresponding multi-year revenue guidance leaves investors with limited visibility into how quickly the company's commercial business can scale to support these spending commitments.
Moderna expects to end 2026 with approximately $9 billion in total liquidity, including cash, investments and undrawn borrowing capacity. While this provides a substantial financial cushion, it does not necessarily indicate that the business is generating sufficient cash internally to sustain its operations and investments. The key question is whether its expanding commercial portfolio can generate enough recurring cash flow to fund its pipeline ambitions without continued reliance on external financing.
An Expanding Portfolio Could Support Revenue Growth for Moderna
Moderna is seeking to reduce its dependence on COVID-19 vaccines by expanding its respiratory portfolio across influenza, RSV and combination vaccines. The company recently launched its influenza vaccine, mFlusiva, in the United States. During the event, management noted that the product recorded more than 110,000 vaccinations during its limited U.S. launch, despite approval coming after the contracting cycle. A broader commercial rollout during the 2027-28 respiratory season could therefore provide a more meaningful contribution to revenues. The company is also looking to expand sales of its next-generation COVID vaccine, mNexspike, and RSV vaccine, mResvia.
International expansion could provide another source of growth. Moderna is looking to strengthen its presence in Europe as a major competitor's vaccine-supply contract expires in 2027, potentially creating an opportunity to capture additional market share. The company estimates the European respiratory vaccine-supply market at approximately 90 million doses across influenza, COVID-19 and RSV. Meanwhile, government partnerships in international markets such as the United Kingdom, Canada, Australia, Mexico and Taiwan are supporting international sales and providing greater revenue visibility.
Despite these diversification efforts, COVID-19 vaccines remain an important contributor to Moderna's commercial business. The company continues to maintain a strong competitive position, supported by its updated vaccines and established distribution network. However, demand has normalized from pandemic-era levels, making sustained growth increasingly challenging. The recent increase in international COVID-19 sales highlights the continued importance of this franchise, but the successful commercialization of newer products will be essential to reducing revenues concentration over time.
Beyond infectious diseases, Moderna's oncology pipeline offers another potential source of future growth. The company’s individualized cancer therapy, intismeran autogene, developed in partnership with Merck (MRK - Free Report) , reported positive phase III results in high-risk melanoma, reducing the risk of recurrence or death by 42%. Both companies are targeting an FDA regulatory submission before the end of 2026, potentially paving the way for approval in 2027. While this could eventually provide a meaningful additional revenue stream, regulatory approval, manufacturing scale-up and commercial adoption remain important uncertainties.
Moderna Faces Stiff Competition in Targeted Markets
Moderna continues to face stiff competition in the COVID-19 vaccine market, where it competes with Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Sanofi/Novavax. As demand for COVID-19 vaccines has normalized, maintaining market share remains important to the company’s respiratory business. Competition could intensify further in the combination vaccines market as manufacturers develop products targeting both influenza and COVID-19, potentially increasing pressure on pricing and market share.
In RSV, Moderna’s mResvia competes with Pfizer’s Abrysvo and GSK’s Arexvy. The seasonal influenza market presents another challenge, with mFlusiva entering a market dominated by established players such as Sanofi, CSL Seqirus and GSK. Competition could become more intense as GSK advances its own mRNA-based flu vaccine following positive phase II results.
MRNA’s Price Performance, Valuation & Estimates
Shares of Moderna have skyrocketed 567% year-to-date, significantly outperforming the industry’s nearly 6% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 29.73 times forward 12-month sales, higher than the industry average of 2.01 times.
Image Source: Zacks Investment Research
Estimates for Moderna’s 2026 loss per share have improved from $8.31 to $7.19 in the past 30 days. During the same time frame, those for 2027 have improved from $4.46 to $3.69.
Image Source: Zacks Investment Research
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.